Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells

The purpose of these studies was to determine whether systemic administration of recombinant interleukin 12 (rIL-12) is able to potentiate an initial, but insufficient T-cell antitumor response. Mice challenged with carcinoma cells engineered to release interleukin 2 (IL-2) and displaying such a res...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1996-02, Vol.56 (3), p.467-470
Main Authors: VAGLIANI, M, RODOLFO, M, CAVALLO, F, PARENZA, M, MELANI, C, PARMIANI, G, FORNI, G, COLOMBO, M. P
Format: Article
Language:English
Subjects:
Adenocarcinoma - immunology
Adenocarcinoma - secretion
Animals
Antineoplastic agents
Biological and medical sciences
Cell Division - physiology
Chemotherapy, Adjuvant
Colonic Neoplasms - immunology
Colonic Neoplasms - secretion
Combined Modality Therapy
DNA, Complementary - genetics
Drug Synergism
Granulocyte-Macrophage Colony-Stimulating Factor - genetics
Granulocyte-Macrophage Colony-Stimulating Factor - immunology
Granulocyte-Macrophage Colony-Stimulating Factor - secretion
Humans
Immunotherapy
Immunotherapy, Adoptive
Interleukin-12 - pharmacology
Interleukin-2 - genetics
Interleukin-2 - immunology
Interleukin-2 - secretion
Killer Cells, Natural - immunology
Lymphocytes, Tumor-Infiltrating - immunology
Medical sciences
Mice
Mice, Inbred BALB C
Pharmacology. Drug treatments
T-Lymphocytes - immunology
Transduction, Genetic
Vaccines - immunology
Vaccines - pharmacology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of these studies was to determine whether systemic administration of recombinant interleukin 12 (rIL-12) is able to potentiate an initial, but insufficient T-cell antitumor response. Mice challenged with carcinoma cells engineered to release interleukin 2 (IL-2) and displaying such a response received single or multiple i.p. injections of rIL-12. This combination of systemic rIL-12 and local IL-2 increased the percentage of mice that rejected two different IL-2 gene-transduced tumors. In another set of experiments more closely resembling a clinical situation, IL-2 gene-transduced tumors were used as vaccines in an attempt to cure mice bearing wild-type parental tumors. The combination of these vaccines with systemic rIL-12 cured mice more effectively than rIL-12 and IL-2 gene-transduced tumor vaccines alone.
ISSN:0008-5472
1538-7445